Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

• Status: Recruiting
• Trial end date: 2030-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Navy General Hospital, Beijing

Criteria

Inclusion criteria:

• Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

Exclusion criteria:

• Involved sites other than the brain, meninges, CSF, or the eyes.

• Age less than 18 years or greater than 75 years.

• Inadequate bone marrow capacity (defined as neutrophils<1.5 ×10^9/L, platelets <100 ×10^9/L, and hemoglobin level< 8 g/dL).

• Known cause of immunosuppression (ie, HIV type I infection).

• Any previous malignancy.

• Creatinine clearance below 60 mL/min.

• Heart insufficiency (NYHA IIIB or IV).

• Uncontrolled infection.

• Noncompensated active pulmonary or liver disease.

• Previously treated for PCNSL, except by corticosteroids.